| Patient | Ida B. Wells |
|---|---|
| Date of birth | 1957-07-16 |
| Identifiers | MRN HR-ET022-SYN; SSN (made up) 000-22-5903 |
| Document date | 2026-11-01 |
| Author | Cordelia Ashworth-Banks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone tests. Concerns: She wants to know exactly how sick her kidneys are, how the number was calculated, and why an earlier result was called normal; She wants to keep working and finish her memoir. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen | One or two tablets up to three times a day as needed | Oral route | 2026-01-05 | active | S |
| Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 2026-01-20 to 2026-03-03 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-20 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-20 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery | One tablet daily, with sick-day rules | Oral route | 2026-02-03 | active | S |
| Losartan 100 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 2026-03-03 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram | 2026-01-05 to 2026-01-05 | completed | S |
| Ultrasound of both kidneys and the bladder | 2026-01-20 to 2026-01-20 | completed | S |
| Kidney diet session with the dietitian: sodium below 2 g a day, protein about 0.8 g per kg, plant-rich meals, no potassium restriction at present | 2026-02-03 to 2026-02-03 | completed | S |
| Advance care planning conversation, about 25 minutes, including kidney treatment options | 2026-02-17 to 2026-02-17 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-01-20 | High-dose influenza vaccine, this season | completed | S |
| 2026-01-20 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-01-20 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-02-17 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-02-17 | Respiratory syncytial virus vaccine, adjuvanted (RSVPreF3), single dose | completed | S |
| 2026-02-17 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-03-03 | COVID-19 vaccine, mRNA, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died in the yellow fever epidemic when she was 16 | D (CLM-0002) | |
| mother | Died in the yellow fever epidemic when she was 16 | D (CLM-0002) | |
| brother | An infant brother died in the same yellow fever epidemic | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| She wants to know exactly how sick her kidneys are, how the number was calculated, and why an earlier result was called normal | active | S |
| She wants to keep working and finish her memoir | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 139 on 2026-03-03; Potassium [Moles/volume] in Serum or Plasma 4.8 on 2026-03-03; Carbon dioxide, total [Moles/volume] in Serum or Plasma 23 on 2026-03-03; Urea nitrogen [Mass/volume] in Serum or Plasma 31 on 2026-03-03; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-01-05; Creatinine [Mass/volume] in Serum or Plasma 1.56 on 2026-03-03; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 36 on 2026-03-03; Cystatin C [Mass/volume] in Serum or Plasma 1.68 on 2026-01-05; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI 2021)/1.73 sq M 38 on 2026-01-05; Albumin/Creatinine [Mass Ratio] in Urine 228 on 2026-01-20; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-01-05; Hemoglobin [Mass/volume] in Blood 11.2 on 2026-01-05; Ferritin [Mass/volume] in Serum or Plasma 168 on 2026-01-05; Iron saturation [Mass Fraction] in Serum or Plasma 24 on 2026-01-05; Calcium [Mass/volume] in Serum or Plasma 9.2 on 2026-01-05; Phosphate [Mass/volume] in Serum or Plasma 3.8 on 2026-01-05; Parathyrin.intact [Mass/volume] in Serum or Plasma 84 on 2026-01-05; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 17 on 2026-01-05; Cholesterol [Mass/volume] in Serum or Plasma 214 on 2026-01-05; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 136 on 2026-01-05; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 2026-01-05; Triglyceride [Mass/volume] in Serum or Plasma 128 on 2026-01-05; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-01-05; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-01-05; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-02-17; Total score [Mini-Cog] 5 on 2026-02-17; Total score [AUDIT-C] 1 on 2026-02-17 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established | resolved | confirmed | R94.4 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney disease | active | confirmed | I12.9 | S — Synthetic modern diagnosis; no blood pressure from her life is recorded. |
| Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7% | active | confirmed | N18.32 | S — Synthetic modern diagnosis linked to the kidney disease recorded at her death. |
| Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tiredness | active | confirmed | D63.1 | S — Synthetic laboratory finding. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normal | active | confirmed | E55.9 | S — Synthetic laboratory finding, part of the mineral and bone check in kidney disease. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-05 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-05 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-05 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | Keep at 22 or above in kidney disease | Normal | S |
| 2026-01-05 | Urea nitrogen [Mass/volume] in Serum or Plasma | 28 | mg/dL | 8-23 mg/dL | High | S |
| 2026-01-05 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-01-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.42 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-01-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 40 | mL/min/{1.73_m2} | 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4 | Low | S |
| 2026-01-05 | Cystatin C [Mass/volume] in Serum or Plasma | 1.68 | mg/L | 0.53-0.95 mg/L | High | S |
| 2026-01-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI 2021)/1.73 sq M | 38 | mL/min/{1.73_m2} | The confirmatory estimate KDIGO prefers when decisions depend on accuracy; 30 to 44 is G3b | Low | S |
| 2026-01-05 | Albumin/Creatinine [Mass Ratio] in Urine | 240 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-01-05 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | Below 5.7% is normal; 6.5% or higher is diabetes | Normal | S |
| 2026-01-05 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | Anemia in women is below 12.0 g/dL | Low | S |
| 2026-01-05 | Ferritin [Mass/volume] in Serum or Plasma | 168 | ng/mL | 30-300 ng/mL | Normal | S |
| 2026-01-05 | Iron saturation [Mass Fraction] in Serum or Plasma | 24 | % | 20-50% | Normal | S |
| 2026-01-05 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-01-05 | Phosphate [Mass/volume] in Serum or Plasma | 3.8 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-01-05 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 84 | pg/mL | 15-65 pg/mL | High | S |
| 2026-01-05 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 17 | ng/mL | Below 20 ng/mL deficient; 20 to 29 insufficient | Low | S |
| 2026-01-05 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-01-05 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 136 | mg/dL | <=99 mg/dL | High | S |
| 2026-01-05 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-01-05 | Triglyceride [Mass/volume] in Serum or Plasma | 128 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-01-05 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-01-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-01-20 | Albumin/Creatinine [Mass Ratio] in Urine | 228 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3) | High | S |
| 2026-02-03 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-03 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-03 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | Keep at 22 or above in kidney disease | Normal | S |
| 2026-02-03 | Urea nitrogen [Mass/volume] in Serum or Plasma | 30 | mg/dL | 8-23 mg/dL | High | S |
| 2026-02-03 | Creatinine [Mass/volume] in Serum or Plasma | 1.5 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-02-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 38 | mL/min/{1.73_m2} | 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4 | Low | S |
| 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-03 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | Keep at 22 or above in kidney disease | Normal | S |
| 2026-03-03 | Urea nitrogen [Mass/volume] in Serum or Plasma | 31 | mg/dL | 8-23 mg/dL | High | S |
| 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 1.56 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 36 | mL/min/{1.73_m2} | 60 or higher without other kidney damage markers; 45 to 59 is G3a, 30 to 44 is G3b, 15 to 29 is G4 | Low | S |
| 2026-02-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-02-17 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-02-17 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-05 | Body height | 157 | cm | S |
| 2026-01-05 | Body weight | 70.4 | kg | S |
| 2026-01-05 | Body mass index (BMI) [Ratio] | 28.6 | kg/m2 | S |
| 2026-01-05 | Systolic blood pressure | 164 | mm[Hg] | S |
| 2026-01-05 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 2026-01-05 | Heart rate | 78 | /min | S |
| 2026-01-05 | Respiratory rate | 16 | /min | S |
| 2026-01-05 | Body temperature | 36.6 | Cel | S |
| 2026-01-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-01-20 | Body height | 157 | cm | S |
| 2026-01-20 | Body weight | 70 | kg | S |
| 2026-01-20 | Body mass index (BMI) [Ratio] | 28.4 | kg/m2 | S |
| 2026-01-20 | Systolic blood pressure | 154 | mm[Hg] | S |
| 2026-01-20 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 2026-01-20 | Heart rate | 76 | /min | S |
| 2026-01-20 | Respiratory rate | 16 | /min | S |
| 2026-01-20 | Body temperature | 36.7 | Cel | S |
| 2026-01-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-02-03 | Body height | 157 | cm | S |
| 2026-02-03 | Body weight | 69.6 | kg | S |
| 2026-02-03 | Body mass index (BMI) [Ratio] | 28.2 | kg/m2 | S |
| 2026-02-03 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2026-02-03 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-02-03 | Heart rate | 74 | /min | S |
| 2026-02-03 | Respiratory rate | 16 | /min | S |
| 2026-02-03 | Body temperature | 36.6 | Cel | S |
| 2026-02-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-02-17 | Body height | 157 | cm | S |
| 2026-02-17 | Body weight | 69.2 | kg | S |
| 2026-02-17 | Body mass index (BMI) [Ratio] | 28.1 | kg/m2 | S |
| 2026-02-17 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-02-17 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-02-17 | Heart rate | 72 | /min | S |
| 2026-02-17 | Respiratory rate | 16 | /min | S |
| 2026-02-17 | Body temperature | 36.6 | Cel | S |
| 2026-02-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-03-03 | Body height | 157 | cm | S |
| 2026-03-03 | Body weight | 68.9 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 72 | /min | S |
| 2026-03-03 | Respiratory rate | 16 | /min | S |
| 2026-03-03 | Body temperature | 36.6 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-01-05 | New patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone tests | finished | S |
| 2026-01-20 | Two-week review of home blood pressure readings, the repeat urine test and the kidney ultrasound, with the nephrology consultation | finished | S |
| 2026-02-03 | Two weeks after starting losartan: potassium, creatinine and blood pressure, and the decision about dapagliflozin | finished | S |
| 2026-02-17 | Subsequent annual wellness visit | finished | S |
| 2026-03-03 | Four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Nephrology consultation for reduced kidney function (race-free eGFR 38) with albuminuria of uncertain cause, a 5-year kidney failure risk above 5% if the disease proves chronic, and APOL1 genetic counseling | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Confirm and stage the kidney disease: race-free eGFR from creatinine with cystatin C, repeat urine albumin-to-creatinine ratio, urinalysis with microscopy, kidney ultrasound, a monoclonal protein screen (serum protein electrophoresis and free light chains), hepatitis B, hepatitis C and HIV tests, and any earlier results she can obtain | completed | GL-KDIGO-CKD-2024, GL-NKF-ASN-2021, GL-CKDEPI-2021 | S |
| Blood pressure: a validated home monitor with readings twice a day for seven days to confirm the diagnosis; sodium below 2 g a day; recheck in two weeks | completed | GL-AHA-HTN-2025, GL-KDIGO-BP-2021, GL-CMID-2026 | S |
| Stop over-the-counter naproxen and use acetaminophen for knee aching; avoid all NSAIDs; tell every clinician and pharmacist about her kidneys before new medicines or contrast dye | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Anemia and mineral and bone checks: hemoglobin with iron studies, calcium, phosphate, intact PTH and 25-hydroxyvitamin D at baseline | completed | GL-KDIGO-CKD-2024, GL-KDIGO-MBD-2017, GL-CMID-2026 | S |
| Baseline ECG, TSH for tiredness, a lipid panel once at diagnosis, A1c to screen for diabetes, and a PHQ-9 | completed | GL-CMID-2026, GL-AHA-HTN-2025, GL-USPSTF-DEP-2023 | S |
| On the nephrologist's advice: losartan 50 mg daily with potassium and creatinine in two weeks, then dapagliflozin 10 mg daily with a further check at two to four weeks, then losartan increased to the highest dose tolerated; sick-day rules for both; atorvastatin 20 mg; vitamin D3 1,000 units daily with PTH and vitamin D again at three months; blood pressure goal below 130/80 and a systolic below 120 if tolerated | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-KDIGO-MBD-2017, GL-CMID-2026 | S |
| APOL1 genetic testing offered after counseling on what a result would and would not change, on privacy, and on what it could mean for relatives; her decision to defer recorded, with the offer left open | completed | GL-KDIGO-CKD-2024 | S |
| Kidney education session on the kidneys and the treatment options if they fail (transplant, home and center dialysis, and conservative kidney management), long before any decision is needed; kidney diet session with the dietitian | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Vaccines for chronic kidney disease: high-dose influenza, PCV20 and two doses of HepB-CpG (she was not immune), then RSV, recombinant zoster and COVID-19, spaced at her request | completed | GL-CDC-IMZ-2026 | S |
| Dapagliflozin 10 mg daily started now that potassium and creatinine are stable on losartan | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Losartan increased to 100 mg; potassium and creatinine in two to four weeks; urine albumin-to-creatinine ratio, hemoglobin, PTH and vitamin D at three months on treatment; nephrology review at three months | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Blood pressure below 130/80 mmHg in the clinic and at home within two months of starting treatment, and lower if tolerated | 2026-03-03 | active | 132/80 in the clinic and 130/78 at home on losartan 50 mg and dapagliflozin; losartan increased to 100 mg | S |
| Urine albumin-to-creatinine ratio lower by at least 30% at the three-month check on treatment | 2026-03-03 | active | 240 and 228 mg/g at baseline; repeat due at three months on treatment | S |
| No NSAIDs or other avoidable kidney harms; every medicine checked against her kidney function | 2026-03-03 | completed | Naproxen stopped at intake; acetaminophen used instead; medicines checked at every visit | S |
| An informed decision about APOL1 genetic testing, made by her after counseling | 2026-01-20 | completed | Counseled at the consultation; she chose to defer the test and may ask for it at any time | S |
| She understands her stage, her risk and the kidney replacement options, and her wishes are recorded, long before any decision is needed | 2026-02-17 | completed | Kidney education session completed; wishes recorded at the annual wellness visit | S |